FindTrial
Sign In

FOLFOX6 TRIAL: TREATMENT OF THE FIRST LINE OF LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER. CLINICAL TRIAL ABOUT BIOMOLECULAR PREDICTIVE FACTORS

FOLFOX6 TRIAL: TREATMENT OF THE FIRST LINE OF LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER. CLINICAL TRIAL ABOUT BIOMOLECULAR PREDICTIVE FACTORS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004339-78-IT
Enrollment
Unknown
Registered
2007-08-10
Start date
2005-02-18
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced and Metastatic Gastric Cancer MedDRA version: 6.1 Level: PT Classification code 10017768

Interventions

Trade Name: FLUOROURACILE TEVA*IV 5FL250MG Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Fluorouracil CAS Number: 61825-94-3 Concentration unit: mg milligram(s) Concentra

Sponsors

AZIENDA OSPEDALIERA POLICLINICO DI MODENA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026